Former President Trump has taken steps to influence the federal government's approach to psychedelic treatments. His directive aims to accelerate access to these therapies for patients in need.
Additionally, Trump has requested a reassessment of the status of psychedelics as controlled substances, which could have significant implications for their availability and research.
This move reflects a growing interest in the potential therapeutic benefits of psychedelics, although the full impact of such reforms remains to be seen.